Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3).’ The study aims to determine if the combination of the investigational drug Mevrometostat and Enzalutamide is more effective than Enzalutamide alone in treating patients with metastatic castration-sensitive prostate cancer (mCSPC) who are androgen receptor pathway inhibitor (ARPI) naïve.
The study is testing two interventions: Mevrometostat, an investigational drug administered orally, and Enzalutamide, a standard treatment for prostate cancer. The purpose is to evaluate the efficacy of this combination therapy in improving patient outcomes.
This is an interventional study with a randomized, parallel assignment model. It employs a quadruple masking approach, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the specific treatments being administered. The primary purpose of the study is treatment-focused.
The study began on April 15, 2025, with the primary completion date yet to be announced. The latest update was submitted on October 14, 2025. These dates are crucial as they mark the progress and current status of the study.
Pfizer’s ongoing study could significantly impact its stock performance, as positive results may enhance investor confidence and market position in the competitive prostate cancer treatment landscape. The study’s outcome could also influence the strategies of competitors in the pharmaceutical industry.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.